Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported 20 hours ago - Updated 2 hours ago - 4 reports

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

First reported 15 hours ago - Updated 15 hours ago - 1 reports

[News] Biomarker predicts treatment resistance in prostate cancer

A marker detectable through a simple blood test can predict resistance to abiraterone and enzalutamide in men with advanced prostate cancer, a prospective US study shows. In patients with a shortened version of the androgen receptor—AR-V7—which could ... [Published Lancet Oncology - 15 hours ago]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Dr. Petrylak on the Results of the Phase II STRIDE Study

Daniel P. Petrylak, MD[embedded content] Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE ... [Published OncLive - Sep 27 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Enzalutamide may offer chemotherapy alternative in metastatic castrationresistant prostate cancer

The United States Food and Drug Association has approved the use of enzalutamide for patients with metastatic castration-resistant prostate cancer (CRPC).Enzalutamide is an androgen receptor inhibitor that is taken orally once a day.It was...Related Biotechnology, ... [Published BioPortfolio - Sep 18 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

FDA Oks New Indication for the Use of XTANDI (enzalutamide) Capsules

Astellas Pharma and Medivation reported that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). According to ... [Published Individual.com - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 3 reports

FDA Grants Expanded Indication for Enzalutamide Xtandi

Related Biotechnology, Pharmaceutical and Healthcare NewsThe oral androgen receptor inhibitor is now approved as first-line therapy for metastatic castration-resistant prostate cancer. FDA ApprovalsOriginal Article: FDA Grants Expanded Indication for ... [Published BioPortfolio - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 15 reports

FDA Grants Expanded Indication for Enzalutamide (Xtandi)

The US Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor enzalutamide ( Xtandi , Astellas/Medivation) as first-line therapy for metastatic castration-resistant prostate cancer (CRPC), the manufacturers said in a joint ... [Published General Medicine eJournal - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 2 reports

Enzalutamide significantly reduces morbidities associated with bone metastases in men with metastatic castration-resistant prostate cancer

Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM ... [Published Medical News Today - Sep 09 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 3 reports

New breakthrough in prostate cancer treatment

A new study reported in the New England Journal of Medicine has revealed that testing of an abnormal protein in the blood could help in the identification of prostate cancer in case of men who cannot be helped by two new drugs.The name of this shortened ... [Published French Tribune - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 2 reports

Blood marker may signal enzalutamide, abiraterone resistance

Detection of AR-V7 in the peripheral blood appears to be a marker of resistance to both enzalutamide and abiraterone treatment in men who have metastatic castration-resistant prostate cancer,... ... [Published Cardiology News - Sep 04 2014]
First reported Sep 01 2014 - Updated Sep 02 2014 - 5 reports

Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis

By Christopher F. Davis :Exelixis, Inc. (NASDAQ: EXEL ) just announced top-line results from the final analysis of its COMET-1 phase 3 pivotal trial of cabozantinib (Cometriq) in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease ... [Published BioPortfolio - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 02 2014 - 2 reports

[News] NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer

, the National Institute for Health and Care Excellence (NICE) recommended enzalutamide, within its marketing authorisation, for the treatment of metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxel-containing chemotherapy, ... [Published Lancet Oncology - Sep 02 2014]

Quotes

...Sharon Shacham, PhD, President and CSO of Karyopharm. "In particular, the clinical activity and safety profile demonstrated in patients with chemotherapy refractory, castrate-resistant prostate cancer were very encouraging as these heavily pretreated patients have no other standard treatment options available. The safety and response data reported at ESMO further support our decision to proceed with Phase 2 studies in this difficult-to-treat patient population."
In a second poster presentation entitled "Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa)" , Selinexor administered to seven heavily-pretreated patients with ovarian cancer was shown to induce durable disease stabilization or tumor size reduction...
...of their disease," said Sef Kurstjens , M D , Ph D , chief medical officer of Astellas Pharma and president of Astellas Pharma Global Development . "We are pleased that these patients now have Xtandi available as a treatment option."
"I was never going to go out there to win the event or break any records" he said

More Content

All (186) | News (152) | Reports (0) | Blogs (33) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Cited Articles - Recent - 4 hours ago]
[News] Biomarker predicts treatment resistance ... [Published Lancet Oncology - 15 hours ago]
[Corrections] Correction to Lancet Oncol 2014; ... [Published Lancet Oncology - 15 hours ago]
[Editorial] Emotion-based medicine or evidence-... [Published Lancet Oncology - 15 hours ago]
XTANDI® (enzalutamide) receives expanded approv... [Published Indianapolis Business Journal - 20 hours ago]
XTANDI® (enzalutamide) receives expanded approv... [Published Pettinga Financial Advisors - 20 hours ago]
XTANDI® (enzalutamide) receives expanded approv... [Published PR Newswire: Health - 20 hours ago]
Karyopharm Announces Clinical Data for Selinexo... [Published Virtual Strategy Magazine - Sep 29 2014]
Karyopharm Announces Clinical Data for Selinexo... [Published Ask.com - Sep 29 2014]
Dr. Petrylak on the Results of the Phase II STR... [Published OncLive - Sep 27 2014]
MEDIVATION : and Astellas Pharma: FDA Grants Ap... [Published 4 Traders - Sep 23 2014]
Below the Belt raises $250,000 [Published Blacktown Sun - Sep 22 2014]
Blood Test for Receptor Predicts Prostate Cance... [Published Lab Medica - Sep 22 2014]
PREVAIL Trial Investigator Discusses Pre-Chemo ... [Published OncLive - Sep 20 2014]
A new era in prostate cancer treatment [Published Irish Medical Times - Sep 18 2014]
Prostate cancer drug therapy: ‘Don’t be afraid ... [Published City of Hope - Sep 18 2014]
Enzalutamide may offer chemotherapy alternative... [Published BioPortfolio - Sep 18 2014]
Enzalutamide may offer chemotherapy alternative... [Published Ecancer Medicalscience - Sep 18 2014]
Xtandi Nabs New Prostate Cancer Indication [Published FDA News - Sep 18 2014]
Tokai Bags $97M For Prostate Cancer Drug in Ups... [Published Xconomy - Sep 17 2014]
AR-V7 linked to treatment resistance in castrat... [Published Orthopedics Today - Sep 16 2014]
FDA News Roundup: Astellas, Sanofi Pasteur, Ore... [Published Pharmaceutical Online - Sep 16 2014]
Studies Help Refine Management of Prostate Cancer [Published The ASCO Post - Sep 15 2014]
Exelixis Announces Results from the COMET-1 Pha... [Published Pharmacy Choice - Sep 15 2014]
FDA Approves Use of Xtandi for Chemotherapy Nav... [Published BioPortfolio - Sep 15 2014]
FDA Oks New Indication for the Use of XTANDI (e... [Published Individual.com - Sep 15 2014]
FDA Approves Use of Xtandi for Chemotherapy Naï... [Published CancerConnect.com - Sep 15 2014]
West Coast Biotech Roundup: Gates, Orexigen, Me... [Published Xconomy - Sep 12 2014]
Pre-chemotherapy indication for Xtandi in prost... [Published PMLive - Sep 12 2014]
Eagerly Awaited Expanded Xtandi Label Should Ac... [Published BioPortfolio - Sep 11 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Cited Articles - Recent - 4 hours ago]
XTANDI® (enzalutamide) receives expanded approv... [Published PR Newswire: Health - 20 hours ago]
FLINT, Mich., Sept. 30, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that XTANDI® has been granted an expanded approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant ...
FDA approves Astellas and Medivation's expanded... [Published PBR - News - Sep 11 2014]
The US Food and Drug Administration (FDA) has granted approval to Astellas Pharma and Medivation's expanded use of Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). ...
Medivation and Astellas win expanded use for pr... [Published Tech Chronicles - Sep 11 2014]
San Francisco pharmaceutical company Medivation, and its partner Astellas Pharma, were celebrating Wednesday after winning federal permission to significantly expand the audience for their prostate cancer drug. The drug, Xtandi or enzalutamide, was first ...
U.S. FDA Approves New Indication for the Use of... [Published PR Newswire: Policy & Public Interest - Sep 10 2014]
TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI® (enzalutamide) ...
1 2 3 4 5 6 7
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.